Opana ER 30 mg (Oxymorphone Extended-Release)

Opana ER is a brand associated with oxymorphone hydrochloride extended-release, an opioid analgesic formerly used for the management of severe and persistent pain requiring around-the-clock opioid treatment when alternative treatment options were inadequate. Oxymorphone extended-release medicines are prescription opioid products and require careful medical supervision.

Patients should not use an extended-release opioid unless it has been specifically prescribed by an appropriately qualified healthcare professional. Treatment decisions depend on the individual’s medical history, pain condition, previous opioid exposure, other medications, and risk factors.

Oxymorphone extended-release carries serious safety risks, including addiction, abuse, misuse, overdose, and potentially fatal respiratory depression. Current labeling also warns against consuming alcohol with oxymorphone extended-release because the combination can produce dangerous and potentially fatal effects. Extended-release tablets must be used exactly as directed and should not be crushed, broken, or otherwise altered.

Patients should tell their healthcare professional about all prescription medicines, over-the-counter products, supplements, and other substances they use. Particular caution is required when opioids are combined with other central nervous system depressants.

Important Product Status

The original branded Opana ER was voluntarily withdrawn from the U.S. market in 2017. FDA materials also indicate that Opana ER is discontinued, so consumers should verify the exact product, manufacturer, approval status, and dispensing source before obtaining any oxymorphone extended-release medication.

Prescription opioids should be obtained only through an appropriately authorized pharmacy and with a valid prescription. Speak with a healthcare professional or pharmacist for current information about available oxymorphone products and appropriate alternatives.